Experiences of patients with age-related macular degeneration receiving anti-vascular endothelial growth factor therapy

a qualitative study

Amy Burton, Rachel Shaw, Jonathan Gibson

Research output: Contribution to journalArticle

Abstract

The societal cost for the average health authority in the United Kingdom for the care of wet age-related macular degeneration (AMD) has been suggested to be around £7.4 million. It is vital that the best possible care based on the best available evidence is provided to reduce the impact of AMD on patients' lives and the financial cost to the health-care system. This study explored the experiences of AMD patients treated with intravitreal ranibizumab injections. Three semistructured interviews were conducted with seven participants over the course of 18 months. Transcripts were analysed using interpretative phenomenological analysis. Analysis identified four themes: preparing for treatment, the treatment process, patient-provider communication, and results of treatment. Patient experiences highlighted the need to move away from the reliance on letters for information provision, and the need for clearer guidelines about when to cease AMD treatment. Interviews highlighted the need for the inclusion of rigorous qualitative evidence with experiential data in future good clinical practice guideline development for AMD.

Original languageEnglish
Pages (from-to)178-188
Number of pages11
JournalBritish Journal of Visual Impairment
Volume31
Issue number3
DOIs
Publication statusPublished - 17 Dec 2013

Fingerprint

Macular Degeneration
Vascular Endothelial Growth Factor A
Interviews
Therapeutics
Intravitreal Injections
Practice Guidelines
Health Care Costs
Communication
Guidelines
Delivery of Health Care
Costs and Cost Analysis

Keywords

  • anti-vascular endothelial growth factor
  • macular degeneration
  • patient experience
  • vision loss

Cite this

@article{f20c6f9b7a07473ba3fb2f8dc37c913f,
title = "Experiences of patients with age-related macular degeneration receiving anti-vascular endothelial growth factor therapy: a qualitative study",
abstract = "The societal cost for the average health authority in the United Kingdom for the care of wet age-related macular degeneration (AMD) has been suggested to be around £7.4 million. It is vital that the best possible care based on the best available evidence is provided to reduce the impact of AMD on patients' lives and the financial cost to the health-care system. This study explored the experiences of AMD patients treated with intravitreal ranibizumab injections. Three semistructured interviews were conducted with seven participants over the course of 18 months. Transcripts were analysed using interpretative phenomenological analysis. Analysis identified four themes: preparing for treatment, the treatment process, patient-provider communication, and results of treatment. Patient experiences highlighted the need to move away from the reliance on letters for information provision, and the need for clearer guidelines about when to cease AMD treatment. Interviews highlighted the need for the inclusion of rigorous qualitative evidence with experiential data in future good clinical practice guideline development for AMD.",
keywords = "anti-vascular endothelial growth factor, macular degeneration, patient experience, vision loss",
author = "Amy Burton and Rachel Shaw and Jonathan Gibson",
year = "2013",
month = "12",
day = "17",
doi = "10.1177/0264619613490517",
language = "English",
volume = "31",
pages = "178--188",
journal = "British Journal of Visual Impairment",
issn = "0264-6196",
publisher = "Association for the Education and Welfare of the Visually Handicapped",
number = "3",

}

Experiences of patients with age-related macular degeneration receiving anti-vascular endothelial growth factor therapy : a qualitative study. / Burton, Amy; Shaw, Rachel; Gibson, Jonathan.

In: British Journal of Visual Impairment, Vol. 31, No. 3, 17.12.2013, p. 178-188.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Experiences of patients with age-related macular degeneration receiving anti-vascular endothelial growth factor therapy

T2 - a qualitative study

AU - Burton, Amy

AU - Shaw, Rachel

AU - Gibson, Jonathan

PY - 2013/12/17

Y1 - 2013/12/17

N2 - The societal cost for the average health authority in the United Kingdom for the care of wet age-related macular degeneration (AMD) has been suggested to be around £7.4 million. It is vital that the best possible care based on the best available evidence is provided to reduce the impact of AMD on patients' lives and the financial cost to the health-care system. This study explored the experiences of AMD patients treated with intravitreal ranibizumab injections. Three semistructured interviews were conducted with seven participants over the course of 18 months. Transcripts were analysed using interpretative phenomenological analysis. Analysis identified four themes: preparing for treatment, the treatment process, patient-provider communication, and results of treatment. Patient experiences highlighted the need to move away from the reliance on letters for information provision, and the need for clearer guidelines about when to cease AMD treatment. Interviews highlighted the need for the inclusion of rigorous qualitative evidence with experiential data in future good clinical practice guideline development for AMD.

AB - The societal cost for the average health authority in the United Kingdom for the care of wet age-related macular degeneration (AMD) has been suggested to be around £7.4 million. It is vital that the best possible care based on the best available evidence is provided to reduce the impact of AMD on patients' lives and the financial cost to the health-care system. This study explored the experiences of AMD patients treated with intravitreal ranibizumab injections. Three semistructured interviews were conducted with seven participants over the course of 18 months. Transcripts were analysed using interpretative phenomenological analysis. Analysis identified four themes: preparing for treatment, the treatment process, patient-provider communication, and results of treatment. Patient experiences highlighted the need to move away from the reliance on letters for information provision, and the need for clearer guidelines about when to cease AMD treatment. Interviews highlighted the need for the inclusion of rigorous qualitative evidence with experiential data in future good clinical practice guideline development for AMD.

KW - anti-vascular endothelial growth factor

KW - macular degeneration

KW - patient experience

KW - vision loss

UR - http://www.scopus.com/inward/record.url?scp=84890164089&partnerID=8YFLogxK

U2 - 10.1177/0264619613490517

DO - 10.1177/0264619613490517

M3 - Article

VL - 31

SP - 178

EP - 188

JO - British Journal of Visual Impairment

JF - British Journal of Visual Impairment

SN - 0264-6196

IS - 3

ER -